Article of the Week, Suggested by the BPDCN International Registry

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the Week Suggested by the BPDCN International Registry-Astghik Voskanyan

•  Real world (RW) study of patients (pts) with relapsed or refractory (RR) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG).
• TAG showed rapid, durable responses and a high response rate in RR BPDCN patients, leading to extended survival in a population with poor prognosis, where previous treatments have been less effective. These real-world findings support TAG as a treatment option for RR BPDCN patients.”

The North American BPDCN Consortium (NABC) is a collaborative group of multidisciplinary experts focused on advancing BPDCN care. Their main goals include increasing awareness, defining MRD testing, and exploring non-HSCT treatment approaches.

They aim to develop combination therapies, understand BPDCN’s pathobiology, address pediatric cases, and improve quality of life measurements. Additionally, the consortium seeks to create risk stratification tools, expand clinical trial access, and secure funding to support future research and treatment innovations in BPDCN.

Real world (RW) study of patients (pts) with relapsed or refractory (RR) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG)

Authors: Marco Herling, Emanuele Angelucci, David Manteigas, Michael Zuurman and Eric Deconinck.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.